Tests an alert for pharmacists to prevent diabetes in people with serious mental illness
Tests a record-based alert that flags adults with serious mental illness at high diabetes risk.
Key facts
- Who runs it
- Kaiser Permanente
- Where
- Pleasanton, United StatesSee the site
- Trial code
- Registry title
- MetSense Pilot and Feasibility
- Status
- Enrolling by invitation
- People taking part
- 20,000 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- MetSense Risk Flag
- Usual Care
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with schizophrenia, another psychotic disorder, or bipolar disorder who are in a clinical pharmacist program at Kaiser Permanente Northern California.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diagnosis of schizophrenia, another psychotic disorder, or bipolar disorder
- Earlier treatment
- Must be included in a clinical pharmacist population management program for serious mental illness within Kaiser Permanente Northern California
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Age 18 or older
- Diagnosed with schizophrenia, another psychotic disorder, or bipolar disorder
- Included in a clinical pharmacist population management program for serious mental illness within Kaiser Permanente Northern California
Where in United States
- KPNC Division of ResearchPleasanton, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.
The 2 groups in the trial
- MetSenseExisting treatment, for comparison
Participants will be managed by clinical pharmacists who are able to view the MetSense risk flag.
Treatment: MetSense Risk Flag
- Usual CareOther group
Participants will receive usual care. They will be managed by clinical pharmacists who are not able to view the MetSense risk flag.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Optimizing Care to Prevent Diabetes and Promote Cardiovascular Health Among Younger Adults With Severe Mental Illness
- Plain-language title
- Tests an alert for pharmacists to prevent diabetes in people with serious mental illnessGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 February 2026